As the global assisted reproductive technology (ART) market expands
rapidly, driven by rising infertility rates and growing access to IVF
treatments, Urofollitropin has become a cornerstone glycoprotein hormone for
follicular development and ovulation induction. A highly purified form of
follicle-stimulating hormone (FSH) derived from postmenopausal women’s urine, it plays a pivotal role in stimulating multiple follicle
growth, improving egg quality, and enhancing ART success rates—with the global
market favoring ultra-pure, luteinizing hormone (LH)-free formulations. Pharmaceutical partners and fertility
clinics worldwide are seeking a trusted Urofollitropin Manufacturer that
delivers consistent quality, strict regulatory compliance, and ART-scenario
tailored solutions. Kangyuan, a leading biopharmaceutical Urofollitropin
Manufacturer with decades of expertise in urinary-derived APIs, stands out with
its proprietary LH-free purification technology, addressing industry pain points
of residual LH and inconsistent bioactivity while serving North America, Europe,
Asia-Pacific, and emerging markets.
What distinguishes Kangyuan as a premier Urofollitropin Manufacturer is its
innovative LH-free purification process, designed to eliminate residual LH and
ensure ultra-high purity— a critical advantage for ART success. Unlike
conventional manufacturers struggling with LH contamination (often exceeding the
1:60 LH/FSH ratio limit), Kangyuan adopts a four-stage
gradient chromatography process, integrating anion exchange, cation exchange,
dye affinity, and gel filtration to sequentially remove impurities, residual
proteins, and trace LH. This advanced technology achieves a Urofollitropin
purity of over 99.5%, a specific activity of no less than 10,000 IU/mg protein, and an LH/FSH ratio of ≤1:100, fully complying with USP, EP,
and ChP standards. Our low-temperature freeze-drying process further preserves
the hormone’s native molecular structure, ensuring consistent bioactivity and
reducing the risk of ovarian hyperstimulation syndrome (OHSS)—a key concern in
ART protocols.
As a global Urofollitropin Manufacturer, Kangyuan excels in navigating
complex regional regulatory frameworks, a critical advantage for partners
seeking seamless market access. In North America, our Urofollitropin complies
with FDA guidelines, supporting Biologics License Application (BLA) and adhering
to strict cGMP requirements, with comprehensive documentation
to streamline market entry for ART reagents. In Europe, we meet EMA regulations
for biopharmaceuticals, leveraging the centralized approval procedure and
providing full supply chain traceability to ensure compliance, making our product a preferred choice for fertility clinics across the
EU. In Asia-Pacific, the fastest-growing ART market, we leverage cost-efficient
production to offer competitive pricing, catering to the
region’s expanding IVF services while maintaining NMPA compliance and strict
quality standards.
Kangyuan’s competitive edge as a Urofollitropin Manufacturer lies in its
stable supply chain, scalable capacity, and ART-tailored customization. We
source raw materials from a standardized collection network, ensuring
high-quality urine from postmenopausal women to maintain product
consistency, and our GMP-certified facilities boast an annual
production capacity capable of meeting global bulk demands, fulfilling both
small-batch R&D orders and large-scale commercial supply. Every batch
undergoes rigorous testing, including LH/FSH ratio validation, purity analysis,
and bioactivity verification, guaranteeing safety and
efficacy for ART use. We also offer flexible customization options, including
different potency specifications (75IU, 150IU) and lyophilized powder
formulations, tailored to regional clinical preferences such
as controlled ovarian stimulation and IVF protocols.
As the global Urofollitropin market grows, driven by aging populations,
rising infertility rates, and expanding access to ART, Kangyuan remains at the forefront of innovation. Our
ongoing R&D focuses on optimizing the LH-free purification process to
further enhance product yield and bioactivity, while expanding regulatory
compliance to cover emerging markets in Latin America and the Middle East.
Backed by decades of expertise in urinary-derived APIs and a global presence in
40+ countries, Kangyuan has become a trusted Urofollitropin Manufacturer for
pharmaceutical companies, fertility clinics, and healthcare providers
worldwide.
Ready to source ultra-pure, LH-free Urofollitropin for ART success? Contact
Kangyuan today to discuss your specific requirements, request samples, or learn
how our innovative purification technology can elevate your reproductive health
products and support your success in the global ART market.